Form Type: 4

SEC EDGAR Link
Accession Number:0001104659-22-072185
Date:2022-06-15
Issuer: ELOXX PHARMACEUTICALS, INC. (ELOX)
Original Submission Date:

Reporting Person:

PAREKH RAJESH B
C/O ELOXX PHARMACEUTICALS, INC
480 ARSENAL WAY, SUITE 130 WATERTOWN, MA 02472

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTIONS (RIGHT TO BUY) 0.26 2022-06-15 deemed execution date A 20,000 (a) 2032-06-15 common stock 20,000 $0.26 20,000 direct
Footnotes
IDfootnote
f1 the stock option vests as to 50% of the underlying shares on june 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter.
f2 the reporting person will assign the economic interests of this grant to advent life sciences llp. the reporting person is a general partner of advent life sciences llp.
WhaleWisdom Logo

Elevate your investments